title: Do Orally Administered Immunoglobulin-Based Agents Represent the Future of IBD Therapeutics?
authors.affiliation: Division of Pediatric Gastroenterology, Nutrition and Liver Diseases, Department of Pediatrics, Hasbro Children's Hospital/Rhode Island Hospital, 593 Eddy Street, Providence, RI, 02903, USA. jshapiro@lifespan.org.|The Warren Alpert School of Medicine, Brown University, Providence, RI, USA. jshapiro@lifespan.org.
authors.forename: Jason M
authors.initials: JM
authors.lastname: Shapiro
authors.affiliation: Division of Pediatric Gastroenterology, Nutrition and Liver Diseases, Department of Pediatrics, Hasbro Children's Hospital/Rhode Island Hospital, 593 Eddy Street, Providence, RI, 02903, USA.|The Warren Alpert School of Medicine, Brown University, Providence, RI, USA.
authors.forename: Basavaraj
authors.initials: B
authors.lastname: Kerur
mesh_terms: D000818:Animals; D001419:Bacteria / Q000276:immunology*; D003092:Colitis / Q000188:drug therapy*; D003106:Colon / Q000187:drug effects*; D005260:Female; D007136:Immunoglobulins / Q000494:pharmacology*; D007422:Intestines / Q000382:microbiology*; D008297:Male; D064307:Microbiota
chemical_list: D007136:Immunoglobulins